Adapting Drug Development During COVID-19
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmas (view full video here). In this section, Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), Gil Van Bokkelen, Ph.D., chairman and CEO of Athersys (NASDAQ: ATHX), Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics (NASDAQ: OVID), and Rachel King, CEO of GlycoMimetics, (NASDAQ: GLYC), share examples of how companies and regulatory agencies have been adapting during the pandemic.
This website uses cookies to ensure you get the best experience on our website. Learn more